Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG

News May 06, 2014

Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).

Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.

Financial terms were not disclosed.

Gene Medication to Treat Spinal Cord Injury

News

After several months of gene medication treatment, rodents were able to use previously paralyzed limbs, a study has found.

Genomic Landscape of Pediatric Cancers

News

Researchers survey the landscape of genetics in pediatric cancer and present opportunities for using genomic information to advance a new era of care for children with cancer.

Muscle Stem Cell Proliferation Regulated by Oscillatory Gene Expression

News

Periodic fluctuations in gene expression, which was previously only known to occur in neural stem cells, has been identified in muscle stem cells. This oscillation is thought to be crucial in helping maintain muscle stem cell numbers.

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free